Remembering Professor José Baselga

Autor Tabernero, J.
Vydáno v ESMO Open (2021)

ESMO pays tribute to Professor José Baselga

Autor Peters, S., Tabernero, J., Cervantes, A., Banerjee, S., Giuliani, R., Lordick, F.
Vydáno v ESMO Open (2021)

Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients.

Autor Mora, J., Gascón, N., Tabernero, J. M., Rodríguez-Espinosa, J., González-Sastre, F.
Vydáno 1996

Pharmacokinetics of phosphomycin during haemofiltration.

Autor Fernandez Lastra, C, Mariño, E L, Dominguez-Gil, A, Tabernero, J M, Grande Villoria, J
Vydáno 1984

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

Autor Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Vydáno 2013

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines

Autor Vilar, E, Scaltriti, M, Balmaña, J, Saura, C, Guzman, M, Arribas, J, Baselga, J, Tabernero, J
Vydáno 2008

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

Autor Elez, E, Hendlisz, A, Delaunoit, T, Sastre, J, Cervantes, A, Varea, R, Chao, G, Wallin, J, Tabernero, J
Vydáno v Br J Cancer (2016)

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

Autor García-Foncillas, J, Alba, E, Aranda, E, Díaz-Rubio, E, López-López, R, Tabernero, J, Vivancos, A
Vydáno v Ann Oncol (2017)

Randomized Phase 3 Study of Panitumumab With FOLFOX4 Compared to FOLFOX4 Alone as 1(st)-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC): The PRIME Trial

Autor Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M.E., Humblet, Y., Cunningham, D., Wolf, M., Gansert, J.
Vydáno 2010

PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma

Autor Siena, S., Tabernero, J., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., Canon, J.-L., Koukakis, R., Demonty, G., Douillard, J.-Y.
Vydáno v Ann Oncol (2016)

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

Autor Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., Tabernero, J.
Vydáno v Ann Oncol (2014)

PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from...

Autor Kisro, J., Cohn, A., Yoshino, T., Van Cutsem, E., Hegewisch-Becker, S., Kullmann, F., Brück, P., Liepa, A., Yang, L., Nasroulah, F., Tabernero, J.
Vydáno v Ann Oncol (2016)

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies

Autor Boeckx, N., Koukakis, R., Op de Beeck, K., Rolfo, C., Van Camp, G., Siena, S., Tabernero, J., Douillard, J.-Y., André, T., Peeters, M.
Vydáno v Ann Oncol (2017)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

Autor Macarulla, T, Cervantes, A, Tabernero, J, Roselló, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B, Jego, V, von Richter, O, Ciardiello, F
Vydáno v Br J Cancer (2015)

PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial

Autor Yoshino, T., Obermannová, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D., Kim Tae, W., Hsu, Y., Yang, L., Ferry, D., Nasroulah, F., Tabernero, J.
Vydáno v Ann Oncol (2016)

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

Autor Castelo-Branco, L., Awada, A., Pentheroudakis, G., Perez-Gracia, J.L., Mateo, J., Curigliano, G., Banerjee, S., Giuliani, R., Lordick, F., Cervantes, A., Tabernero, J., Peters, S.
Vydáno v ESMO Open (2021)

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: r...

Autor Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero , R.
Vydáno v Clin Transl Oncol (2016)

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

Autor Serna, G., Ruiz-Pace, F., Hernando, J., Alonso, L., Fasani, R., Landolfi, S., Comas, R., Jimenez, J., Elez, E., Bullman, S., Tabernero, J., Capdevila, J., Dienstmann, R., Nuciforo, P.
Vydáno v Ann Oncol (2020)

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six ran...

Autor Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., Cervantes, A., Ciardiello, F.
Vydáno v Ann Oncol (2017)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

Autor Cherny, N I, Sullivan, R, Dafni, U, Kerst, J M, Sobrero, A, Zielinski, C, Piccart, M J, Bogaerts, J, Tabernero, J, Latino, N J, de Vries, E G E
Vydáno v ESMO Open (2016)